Dear Dr. Kollath:

Please refer to your supplemental new drug application (sNDA) dated and received December 17, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Levaquin (levofloxacin) 250 mg, 500 mg, and 750 mg Tablets.

This Prior Approval supplemental new drug application provides for revisions to the prescribing information (PI) as follows:

The HIGHLIGHTS OF PRESCRIBING INFORMATION, USE IN SPECIFIC POPULATIONS (8) section, Pregnancy (8.1) subsection and Lactation (8.2) subsection and PATIENT COUNSELING INFORMATION (17) section were revised to comply with the Pregnancy and Lactation Labeling Rule (PLLR).

The CLINICAL PHARMACOLOGY (12) section, Clinical Microbiology (12.4) subsection, was updated to be consistent with the FDA Guidance.

In addition, the DOSAGE AND ADMINISTRATION (2) section, Important Administration Instructions (2.5) subsection, was updated to be consistent with the Medication Guide.

The Medication Guide has also been updated to be in agreement with the revisions made to the prescribing information. Minor editorial changes and clarifications were made throughout the PI.
APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm)

U.S. Food and Drug Administration
Silver Spring, MD 20993
[www.fda.gov](http://www.fda.gov)
If you have any questions, call Fariba Izadi, PharmD, Senior Regulatory Project Manager, at (301) 796-0563.

Sincerely,

{See appended electronic signature page}

Joseph G. Toerner, M.D., M.P.H.
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
- Content of Labeling
  - Prescribing Information
  - Medication Guide
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOSEPH G TOERNER
06/28/2019 12:30:22 PM